Who Owns Piramal Critical Care?

• Parent Company: Piramal Pharma Limited
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NSE: PPLPHARMA

• Founded: 2010
• Founders: Piramal Pharma (internal development)

• Founded: 1988
• Headquarters: Mumbai, India
• Company Type: Publicly Traded
• Stock: NSE: PPLPHARMA
• Revenue: approximately INR 82 billion (FY2024)
• Employees: Approximately 10,000

Visit Piramal Pharma Limited website

• Headquarters: Mumbai, India
• Manufacturing / Operations: India, United States, United Kingdom, Europe

Piramal Critical Care operates under Piramal Pharma Limited's comprehensive sustainability framework, which is built on four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. The company has embedded sustainability into its core business strategy, moving beyond basic Environmental, Social and Governance (ESG) compliance to create measurable impact across its operations and value chain.

Environmental Sustainability: Piramal Critical Care maintains state-of-the-art manufacturing facilities in the US and India that comply with environmental regulations and sustainability standards. The company focuses on responsible manufacturing practices, waste reduction, and energy efficiency across its production sites. As part of Piramal Pharma's commitment to environmental stewardship, the division participates in corporate-wide initiatives to minimize environmental impact while maintaining high-quality pharmaceutical production standards.

Quality Excellence and Regulatory Compliance: The division has successfully cleared periodic inspections by regulatory authorities including the US FDA, UK MHRA, and other global regulators. In 2025, Piramal Pharma's Lexington facility in Kentucky received a US FDA Form-483 with four observations classified as Voluntary Action Indicated (VAI), relating to procedural enhancements rather than critical manufacturing deficiencies. The company demonstrated its commitment to compliance by preparing detailed responses within regulatory timelines and working closely with the FDA to address all observations.

Corporate Social Responsibility: Piramal Critical Care collaborates with the Piramal Foundation and various partner organizations to provide hope and resources to those in need. The division maintains its commitment to corporate social responsibility alongside Piramal Group, actively participating in community engagement programs and environmental care initiatives. This commitment extends beyond regulatory compliance to include meaningful contributions to community development and social welfare.

Ethical Business Practices: With a culturally diverse workforce of more than 400 employees across 16 countries, Piramal Critical Care maintains strong ethical standards and corporate governance practices. The company's stakeholder-centric approach ensures that business decisions consider the interests of patients, healthcare providers, employees, communities, and shareholders. This ethical framework guides the company's operations across its global footprint in over 100 countries.

Sustainable Growth Strategy: Piramal Critical Care is focused on achieving sustainable and profitable growth for all stakeholders while delivering critical care solutions to patients and healthcare providers globally. The division's expansion strategy includes new product additions in the critical care space, maintaining its commitment to quality, compliance, and sustainable business practices throughout its growth trajectory.

Patient-Centric Approach: The company's commitment to "Saving and improving patients' lives" extends beyond its purpose statement to guide its sustainability initiatives. Piramal Critical Care's patient centricity campaigns and healthcare professional engagement programs demonstrate its dedication to putting patients at the center of its business decisions and sustainability efforts.

Piramal Critical Care has achieved significant recognition both for its market leadership in inhalational anesthetics and its commitment to sustainability excellence. The division's awards and acknowledgments reflect its position as a global leader in critical care pharmaceuticals and its dedication to corporate responsibility and sustainable business practices.

Sustainability Excellence Recognition: In 2025, Piramal Pharma Limited achieved a notable score increase on the S&P Global Corporate Sustainability Assessment (CSA), one of the world's most respected global sustainability benchmarking frameworks. This achievement reflects the company's successful integration of ESG principles into its core business strategy and demonstrates Piramal Critical Care's contribution to the company's overall sustainability performance.

Manufacturing and Quality Standards: Piramal Critical Care's manufacturing facilities have successfully cleared inspections by multiple global regulatory authorities, including the US FDA, UK MHRA, and other regulatory bodies. These successful inspections represent recognition of the division's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its global operations.

Market Leadership Recognition: The division is consistently recognized as one of the leaders in inhaled anesthetics and a global player in hospital generics. This market leadership position is acknowledged through industry reports and analyst coverage that highlight Piramal Critical Care's strong presence in the critical care pharmaceuticals market and its competitive advantages in product quality and global distribution.

Fourth Sustainability Report Achievement: Piramal Pharma Limited released its fourth annual Sustainability Report in 2025, highlighting the company's shift from basic ESG compliance to integrating sustainability into its core business strategy. This comprehensive report outlines progress across 28 material topics supported by 50+ time-bound targets, demonstrating measurable impact in near- and medium-term sustainability goals.

Global Workforce Diversity Recognition: Piramal Critical Care's culturally diverse workforce of more than 400 employees representing 20 nationalities across 16 countries has been recognized as a strength in global pharmaceutical operations. This diversity contributes to the company's ability to serve healthcare markets globally and maintain cultural sensitivity in its business practices.

Patient Centricity Innovation: The division's patient centricity campaigns and healthcare professional engagement programs have received positive recognition for their innovative approach to stakeholder engagement. These initiatives demonstrate Piramal Critical Care's commitment to putting patients at the center of its business decisions and sustainability efforts.

Regulatory Compliance Excellence: Despite receiving a Form-483 in 2025, Piramal Critical Care's prompt and comprehensive response to FDA observations demonstrated its commitment to regulatory compliance excellence. The VAI classification (less severe than OAI) and the company's proactive approach to addressing regulatory requirements reflect its dedication to maintaining high compliance standards.

Piramal Critical Care has maintained a relatively clean operational record throughout its history, with the most significant regulatory issue being a 2025 FDA Form-483 observation at its Lexington facility. The division's focus on quality manufacturing and regulatory compliance has helped it avoid major product recalls or serious controversies that commonly affect pharmaceutical companies operating in highly regulated markets.

FDA Form-483 Observation (2025): The most notable regulatory issue occurred in 2025 when Piramal Pharma's Lexington, Kentucky facility received a US FDA Form-483 following a Good Manufacturing Practices (GMP) inspection. The inspection resulted in four regulatory observations classified as Voluntary Action Indicated (VAI), focusing on procedural enhancements rather than critical manufacturing deficiencies. The observations were specifically related to procedural improvements rather than issues with product quality or safety.

Regulatory Classification and Response: The VAI classification indicated that the FDA found objectionable conditions but was not prepared to take or recommend administrative or regulatory action. This classification is less severe than an Official Action Indicated (OAI) status, which would require more immediate corrective measures. Piramal Pharma confirmed it was preparing a detailed response to address all observations within the stipulated regulatory timelines, demonstrating the company's commitment to compliance.

Manufacturing Compliance Track Record: Despite the 2025 FDA observation, Piramal Critical Care has maintained a strong track record of regulatory compliance. The division's manufacturing facilities in the US and India have successfully cleared periodic inspections by multiple regulatory authorities, including the US FDA, UK MHRA, and other global regulators. This compliance record reflects the company's investment in quality systems and manufacturing excellence.

No Major Product Recalls: Piramal Critical Care has not experienced any major product recalls that would indicate systemic quality issues. The company's focus on inhalational anesthetics and complex hospital generics requires stringent quality control measures, and the division has maintained compliance with these requirements throughout its operations.

Limited Public Controversies: Unlike some pharmaceutical companies that have faced significant public controversies related to pricing, marketing practices, or ethical issues, Piramal Critical Care has maintained a low public profile with minimal controversies. The company's business-to-business focus on healthcare providers and hospitals, combined with its emphasis on essential critical care medications, has helped it avoid the types of public scrutiny that affect more consumer-facing pharmaceutical companies.

Regulatory Environment Navigation: Operating in over 100 countries requires navigating complex regulatory environments, and Piramal Critical Care has successfully managed these challenges without major compliance failures. The division's experience with multiple regulatory authorities and its established quality systems have enabled it to maintain compliance across diverse international markets.

Stakeholder Management: The company's stakeholder-centric approach has helped it maintain positive relationships with regulators, healthcare providers, and other key stakeholders. This proactive stakeholder engagement has contributed to the division's ability to address regulatory issues promptly and maintain trust in its operations and products.